The formation of pancreatic pseudocysts and (pseudo-)aneurysms of intestinal vessels are rare but life-threatening complications in acute and chronic pancreatitis. Here we report the rare case of a patient suffering from chronic pancreatitis with an arterial pseudoaneurysm within a pancreatic pseudocyst and present its successful therapeutic management by angioembolization to prevent critical bleeding. A 67-year-old male with a history of chronic pancreatitis presented with severe acute abdominal pain and vomiting to the emergency department. Seven weeks prior to the present admission, a CT scan had displayed a pancreatic pseudocyst with a maximum diameter of 53 mm. A laboratory examination revealed an elevated white blood cell count (15.40 × 103/μL), as well as elevated serum lipase (191 U/L), bilirubin (1.48 mg/dL), and blood glucose (353 mg/dL) levels. Sonographically, the previously described pancreatic pseudocyst revealed a slightly increased maximum diameter of 65 mm and an inhomogeneous echo of the cystic content. A contrast-enhanced CT scan showed a further increase in maximum diameter to 70 mm of the known pseudocyst. Inside the pseudocyst, a pseudoaneurysm originating from the splenic artery with a maximum diameter of 41 mm was visualized. After interdisciplinary consultation, prophylactic coil embolization of the splenic artery was immediately performed. The pseudoaneurysm was shut off from blood supply by back-door/front-door occlusion employing 27 coils, resulting in complete exclusion of the pseudoaneurysm from the circulation. Pseudoaneurysms are a rare complication of acute and chronic pancreatitis which has been shown to be efficiently treated by coil embolization.

Pancreatic pseudocyst formation is a well-known complication in chronic and acute pancreatitis that can cause local complications and pain. The prevalence of pseudocysts among patients with chronic pancreatitis approximates 20–40%; however, this may be overestimated due to changes in the nomenclature of peripancreatic fluid collections in the revised Atlanta classification [1, 2]. In patients with acute pancreatitis, the development of a pancreatic pseudocyst is extremely rare and usually occurs delayed after > 4 weeks [2]. Pancreatic pseudocysts are defined as localized fluid collections in (peri-)pancreatic tissue which contain a fluid rich in pancreatic enzymes without any solid material and have a well-defined, nonepithelialized wall consisting of fibrous and granulated tissue. They are to be distinguished from acute peripancreatic fluid collections, acute necrotic collections, and walled-off necrosis. Diagnoses can usually be made based on morphologic criteria [2, 3].

Another complication in patients suffering from acute or chronic pancreatitis is the formation of (pseudo-)aneurysms of intestinal vessels, a rare but life-threatening complication if bleeding of the pseudoaneurysm occurs, with a mortality of 30–50% [4-10]. The formation of (pseudo-)aneurysms and arrosions of vessels are triggered by inflammation of the pancreas and the surrounding tissue, extravasation of proteolytic enzymes, formation of pseudocysts, extensive necrosis, or abscesses [11, 12].

Here we report the clinical case of a patient with an arterial pseudoaneurysm within a pancreatic pseudocyst and show the prophylactic therapy to prevent critical bleeding.

A 67-year-old male with a 3.5-year history of chronic alcoholic pancreatitis presented with severe acute abdominal pain and vomiting to the emergency department of a teaching hospital. The patient had experienced a first episode of acute alcoholic pancreatitis 7 years previously, and at least three subsequent acute attacks of chronic pancreatitis within the last 3.5 years. Seven weeks prior to the present admission, he had suffered from the last acute attack, and a CT scan revealed a pancreatic pseudocyst at the pancreatic tail with a maximum diameter of 53 mm. There was no indication for intervention at that time. The patient reported an alcohol intake of 1–2 L of beer per day and hard liquor intake once a month as well as regular cigarette smoking (45 pack-years). The patient was on oral anticoagulation due to atrial fibrillation and had been suffering from arterial hypertension and insulin-dependent diabetes mellitus for 3.25 years. He reported reduced enteral food intake due to abdominal pain, particularly postprandially, and a weight loss of 20 kg (24%) within the previous 12 months without night sweat.

On admission, a blood pressure of 190/89 mm Hg and a regular heartbeat (56 bpm) were measured. He had no fever, his body height was 180 cm, and his body weight 62 kg (BMI 19.1).

Laboratory examination revealed an elevated white blood cell count (15.40 × 103/μL), as well as elevated serum lipase (191 U/L), bilirubin (1.48 mg/dL), and blood glucose (353 mg/dL) levels. The international normalized ratio was 1.2.

Sonographically, the previously described pancreatic pseudocyst revealed a slightly increased maximum diameter of 65 mm and an inhomogeneous echo of the cystic content (Fig. 1a, b). Color-coded Doppler sonography showed a turbulent blood flow in parts of the cyst (Fig. 1c).

Fig. 1.

a, b Transabdominal ultrasound showing a pancreatic pseudocyst with a maximum diameter of 65 mm and an inhomogeneous echo of the cystic content. c Color-coded Doppler sonography showed a turbulent blood flow in parts of the cyst.

Fig. 1.

a, b Transabdominal ultrasound showing a pancreatic pseudocyst with a maximum diameter of 65 mm and an inhomogeneous echo of the cystic content. c Color-coded Doppler sonography showed a turbulent blood flow in parts of the cyst.

Close modal

The patient was transferred to our tertiary care center for further evaluation and therapy. A contrast-enhanced CT scan at admission (Fig. 2) showed multiple calcifications in the head and body of the pancreas, as well as an irregularly widened pancreatic duct as signs of a chronic pancreatitis. There were no signs of an acute pancreatitis. The known pseudocyst showed a further increase in maximum diameter to 70 mm (arrows). Inside the pseudocyst, a pseudoaneurysm originating from the splenic artery with a maximum diameter of 41 mm was visualized (asterisk), classified as type IIA2 [13]. After interdisciplinary consultation, prophylactic coil embolization of the splenic artery was immediately performed to prevent spontaneous bleeding. The splenic artery was accessed via a right transfemoral approach (Fig. 3a–c). The pseudoaneurysm was shut off from blood supply by back-door/front-door occlusion employing 27 coils, resulting in complete exclusion of the pseudoaneurysm from the circulation (Fig. 3d).

Fig. 2.

Contrast-enhanced CT scan showing a pancreatic pseudocyst with a maximum diameter of 70 mm (arrows). Inside the pseudocyst is a pseudoaneurysm originating from the splenic artery with a maximum diameter of 41 mm (asterisk).

Fig. 2.

Contrast-enhanced CT scan showing a pancreatic pseudocyst with a maximum diameter of 70 mm (arrows). Inside the pseudocyst is a pseudoaneurysm originating from the splenic artery with a maximum diameter of 41 mm (asterisk).

Close modal
Fig. 3.

a–c Digital subtraction angiography with a right transfemoral access showing the splenic artery and a pseudoaneurysm. d The pseudoaneurysm was shut off from blood supply by back-door/front-door occlusion employing 27 coils, resulting in complete exclusion of the pseudoaneurysm from the circulation.

Fig. 3.

a–c Digital subtraction angiography with a right transfemoral access showing the splenic artery and a pseudoaneurysm. d The pseudoaneurysm was shut off from blood supply by back-door/front-door occlusion employing 27 coils, resulting in complete exclusion of the pseudoaneurysm from the circulation.

Close modal

Six weeks after coil embolization, a control CT scan showed a stable condition of the pseudocyst without any signs of reperfusion of the pseudoaneurysm or of infection. There were no signs of infarction of the spleen, with good arterial circulation arising from strong collaterals.

In this case report, we described the very rare situation of an arterial pseudoaneurysm within a pancreatic pseudocyst in a patient suffering from chronic pancreatitis and report on its successful, prophylactic therapy to prevent critical bleeding.

Pancreatic pseudocysts often do not need any therapy, as up to 60% of them resolve spontaneously [14]. In case of complications such as abdominal pain, jaundice, splenic vein thrombosis, infection, or impression of the stomach with early satiety, weight loss, and nausea/vomiting, drainage might be indicated [1, 15]. According to a recent review, endoscopic ultrasound-guided drainage is the optimal drainage approach in uncomplicated pseudocysts that are located adjacent to the stomach or duodenum. However, radiologic or surgical drainage might be indicated in complicated cases.

Regarding intestinal pseudoaneurysms, the optimal therapeutic strategy, including arterial embolization and surgical procedures, is still controversial [9, 10]. Nevertheless, based on the widespread availability and minimal invasiveness, contrast-enhanced CT and digital subtraction angiography have been widely used to detect visceral arterial bleeding sites. Furthermore, due to the improved technical capabilities of interventional radiology, angioembolization should be considered as the first-line therapy to stop the bleeding in patients with bleeding pseudoaneurysms [9, 10]. Due to the infrequency of arterial pseudoaneurysms, data on diagnostics and prophylactic therapy to prevent bleeding are rare. Arterial pseudoaneurysms in pancreatitis are associated with nonspecific symptoms, requiring a high degree of suspicion for an early diagnosis [16]. An individualized diagnostic approach combining sound anamnesis, thorough clinical examination, and technical approaches such as endoscopic ultrasound, CT, or MRI are mandatory. According to the sparse literature on this topic, endovascular intervention is highly effective and should be the preferred treatment option [17, 18].

Written informed consent was obtained from the patient.

All authors have no conflict of interest to declare.

1.
Ramsey
ML
,
Conwell
DL
,
Hart
PA
.
Complications of Chronic Pancreatitis
.
Dig Dis Sci
.
2017
Jul
;
62
(
7
):
1745
50
.
[PubMed]
0163-2116
2.
Banks
PA
,
Bollen
TL
,
Dervenis
C
,
Gooszen
HG
,
Johnson
CD
,
Sarr
MG
, et al;
Acute Pancreatitis Classification Working Group
.
Classification of acute pancreatitis—2012: revision of the Atlanta classification and definitions by international consensus
.
Gut
.
2013
Jan
;
62
(
1
):
102
11
.
[PubMed]
0017-5749
3.
Lambiase
LR
,
Anand
BS
,
Greenwald
D
.
Pancreatic Pseudocysts
.
Medscape
;
2017
.
4.
Andersson
E
,
Ansari
D
,
Andersson
R
.
Major haemorrhagic complications of acute pancreatitis
.
Br J Surg
.
2010
Sep
;
97
(
9
):
1379
84
.
[PubMed]
0007-1323
5.
Carr
JA
,
Cho
JS
,
Shepard
AD
,
Nypaver
TJ
,
Reddy
DJ
.
Visceral pseudoaneurysms due to pancreatic pseudocysts: rare but lethal complications of pancreatitis
.
J Vasc Surg
.
2000
Oct
;
32
(
4
):
722
30
.
[PubMed]
0741-5214
6.
White
AF
,
Baum
S
,
Buranasiri
S
.
Aneurysms secondary to pancreatitis
.
AJR Am J Roentgenol
.
1976
Sep
;
127
(
3
):
393
6
.
[PubMed]
0361-803X
7.
Hsu
JT
,
Yeh
CN
,
Hung
CF
,
Chen
HM
,
Hwang
TL
,
Jan
YY
, et al
Management and outcome of bleeding pseudoaneurysm associated with chronic pancreatitis
.
BMC Gastroenterol
.
2006
Jan
;
6
(
1
):
3
.
[PubMed]
1471-230X
8.
El Hamel
A
,
Parc
R
,
Adda
G
,
Bouteloup
PY
,
Huguet
C
,
Malafosse
M
.
Bleeding pseudocysts and pseudoaneurysms in chronic pancreatitis
.
Br J Surg
.
1991
Sep
;
78
(
9
):
1059
63
.
[PubMed]
0007-1323
9.
Phillip
V
,
Rasch
S
,
Gaa
J
,
Schmid
RM
,
Algül
H
.
Spontaneous bleeding in pancreatitis treated by transcatheter arterial coil embolization: a retrospective study
.
PLoS One
.
2013
Aug
;
8
(
8
):
e72903
.
[PubMed]
1932-6203
10.
Chiang
KC
,
Chen
TH
,
Hsu
JT
.
Management of chronic pancreatitis complicated with a bleeding pseudoaneurysm
.
World J Gastroenterol
.
2014
Nov
;
20
(
43
):
16132
7
.
[PubMed]
1007-9327
11.
Flati
G
,
Salvatori
F
,
Porowska
B
,
Talarico
C
,
Flati
D
,
Proposito
D
, et al
Severe hemorrhagic complications in pancreatitis
.
Ann Ital Chir
.
1995
Mar-Apr
;
66
(
2
):
233
7
.
[PubMed]
0003-469X
12.
Flati
G
,
Andrén-Sandberg
A
,
La Pinta
M
,
Porowska
B
,
Carboni
M
.
Potentially fatal bleeding in acute pancreatitis: pathophysiology, prevention, and treatment
.
Pancreas
.
2003
Jan
;
26
(
1
):
8
14
.
[PubMed]
0885-3177
13.
Pang
TC
,
Maher
R
,
Gananadha
S
,
Hugh
TJ
,
Samra
JS
.
Peripancreatic pseudoaneurysms: a management-based classification system
.
Surg Endosc
.
2014
Jul
;
28
(
7
):
2027
38
.
[PubMed]
0930-2794
14.
Teoh
AY
,
Dhir
V
,
Kida
M
,
Yasuda
I
,
Jin
ZD
,
Seo
DW
, et al
Consensus guidelines on the optimal management in interventional EUS procedures: results from the Asian EUS group RAND/UCLA expert panel
.
Gut
.
2018
Jul
;
67
(
7
):
1209
28
.
[PubMed]
0017-5749
15.
Braha
J
,
Tenner
S
.
Fluid Collections and Pseudocysts as a Complication of Acute Pancreatitis
.
Gastrointest Endosc Clin N Am
.
2018
Apr
;
28
(
2
):
123
30
.
[PubMed]
1052-5157
16.
Martins
A
,
Goncalves
A
,
Passos
P
, et al
Splenic Artery Pseudoaneurysm
.
J Gastrointest Surg
.
2017
.
[PubMed]
1091-255X
17.
Sawachika
H
,
Fujita
S
,
Mukai
T
, et al
IgG4-related autoimmune pancreatitis complicated by splenic artery pseudoaneurysm.
BMJ Case Rep
2018
;2018.
18.
Zabicki
B
,
Limphaibool
N
,
Holstad
MJ
,
Juszkat
R
.
Endovascular management of pancreatitis-related pseudoaneurysms: A review of techniques
.
PLoS One
.
2018
Jan
;
13
(
1
):
e0191998
.
[PubMed]
1932-6203
Open Access License / Drug Dosage / Disclaimer
This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.